Saltar al contenido principal
ALSA Research

Nueva York, NY

Weight Loss Maintenance Study for People Taking Ozempic or Wegovy

Have you lost weight taking Ozempic or Wegovy? We are conducting a new clinical research study assessing a new investigational treatment for preventing weight regain after stopping treatment with semaglutide (Ozempic or Wegovy). Study-related care may be provided at no cost, and compensation may be available for time, travel, and other expenses. Space is limited—apply today to see if you qualify.

Por ahora, la información de este estudio solo está disponible en inglés.

Edades elegibles

Adults 18-75

Compensación

Available for time and travel

Quién es elegible

• Are between 18 and 75 years of age • Have been taking semaglutide (Ozempic or Wegovy) for at least 3 months • Had a documented BMI of 30 kg/m² or higher before starting your GLP-1, or BMI of 27 kg/m² with one weight-related comorbidity like hypertension, high cholesterol, cardiovascular disease or obstructive sleep apnea • Have reduced at least 10% of your body weight since you’ve started taking Ozempic • Are willing to discontinue use of Ozempic/Wegovy during the study Additional criteria may apply. A full list of study criteria will be reviewed with you by our team.

Qué implica

Qualified participants may receive: • Access to a new investigational medicine • Study-related care at no cost • Compensation may be available for time, travel, and other expenses • The opportunity to help advance potential new options for reducing body weight Participation is voluntary, and health insurance is not required.

Dónde se realiza este estudio

ALSA Research – Manhattan

425 5th Avenue, 6th Floor, Unit 602, New York, NY 10016

Ver en ClinicalTrials.gov (NCT07837973) ↗

← Volver a todos los estudios en Nueva York, NY